Concepedia

Charles R. Dunlop

CR

6

Publications

318

Citations

6

H-Index

2018

Active since

Affiliations

University of Cambridge(Current)

AstraZeneca (United Kingdom)

Harvard University

Cancer Research UK

Massachusetts General Hospital

Charles R. Dunlop is an author at University of Cambridge specializing in tumor biology, cancer research, and molecular imaging.

ORCID

Top concepts

Publications per year

2018–2022

6

Publications

6

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine <i>In Vitro</i> and <i>In Vivo</i> to Induce Pancreatic Ductal Adenocarcinoma Regression

Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson et al. · Molecular Cancer Therapeutics · 2018 · 106 citations · Full text

Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models

Charles R. Dunlop, Yann Wallez, Timothy Isaac Johnson et al. · British Journal of Cancer · 2020 · 56 citations · Full text

p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulators

Charles N. Birts, Arindam Banerjee, Matthew Darley et al. · Science Signaling · 2020 · 47 citations · Full text

Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine

Siang‐Boon Koh, Yann Wallez, Charles R. Dunlop et al. · Cancer Research · 2018 · 42 citations · Full text

Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging

Nicole Strittmatter, Frances M. Richards, Alan Race et al. · Analytical Chemistry · 2022 · 38 citations · Full text

, , +21

Rows per page

1–5 of 6